Literature DB >> 17258066

Quantitative analysis of Howell-Jolly bodies in children with sickle cell disease.

Virginia L Harrod1, Thad A Howard, Sherri A Zimmerman, Stephen D Dertinger, Russell E Ware.   

Abstract

OBJECTIVES: Although functional asplenia in sickle cell disease (SCD) begins early in life and has important clinical consequences, quantitative measurement of splenic function is not readily available. A novel high-throughput flow cytometric method for quantitating Howell-Jolly bodies (HJB) has been developed which isolates HJB-containing CD71(+) and CD71(-) erythrocytes. Analysis of these cell populations allows quantitative measurement of splenic filtrative function and possible chromosomal damage.
METHODS: Blood specimens from 147 children with SCD were analyzed using a high-throughput flow cytometric method. Enumeration of the following populations was accomplished: 1) CD71(+) reticulocytes among total erythrocytes, identifying the youngest erythroid cell population; 2) HJB-containing CD71(+) reticulocytes, which isolate young erythrocytes containing micronuclei as an index of cytogenetic damage; and 3) HJB-containing CD71(-) erythrocytes, identifying older erythrocytes containing micronuclei, indirectly measuring splenic function.
RESULTS: Children with HbSC (n = 24) had slightly elevated HJB frequencies, while children with HbSS (n = 125) had highly elevated frequencies within CD71(+) cells (0.44% +/- 0.40%, normal 0.12% +/- 0.06%, p < 0.001) and CD71(-) cells (2493 +/- 2303 per million RBC, normal 20 +/- 11, p < 0.001). Using a multiple regression model, the frequency of HbSS CD71(+) reticulocytes containing HJB was significantly influenced by hydroxyurea use (p < 0.0001), age (p = 0.0288), and splenectomy (p = 0.0498). Similarly, mature CD71(-) erythrocytes containing HJB were positively correlated with hydroxyurea (p = 0.0001), age (p < 0.0001), and splenectomy (p = 0.0104).
CONCLUSIONS: HJB quantitation by flow cytometry is a novel assay for measuring splenic function and may be valuable for investigating the efficacy and safety of therapeutic options for children with SCD.

Entities:  

Mesh:

Substances:

Year:  2007        PMID: 17258066     DOI: 10.1016/j.exphem.2006.09.013

Source DB:  PubMed          Journal:  Exp Hematol        ISSN: 0301-472X            Impact factor:   3.084


  19 in total

1.  Genotoxicity associated with hydroxyurea exposure in infants with sickle cell anemia: results from the BABY-HUG Phase III Clinical Trial.

Authors:  Patrick T McGann; Jonathan M Flanagan; Thad A Howard; Stephen D Dertinger; Jin He; Anita S Kulharya; Bruce W Thompson; Russell E Ware
Journal:  Pediatr Blood Cancer       Date:  2011-10-19       Impact factor: 3.167

2.  A novel non-invasive method to measure splenic filtration function in humans.

Authors:  Sara El Hoss; Michaël Dussiot; Olivier Renaud; Valentine Brousse; Wassim El Nemer
Journal:  Haematologica       Date:  2018-06-07       Impact factor: 9.941

3.  Renal function in infants with sickle cell anemia: baseline data from the BABY HUG trial.

Authors:  Russell E Ware; Renee C Rees; Sharada A Sarnaik; Rathi V Iyer; Ofelia A Alvarez; James F Casella; Barry L Shulkin; Eglal Shalaby-Rana; C Frederic Strife; John H Miller; Peter A Lane; Winfred C Wang; Scott T Miller
Journal:  J Pediatr       Date:  2010-01       Impact factor: 4.406

4.  Antibody response to a T-cell-independent antigen is preserved after splenic artery embolization for trauma.

Authors:  D C Olthof; A J J Lammers; E M M van Leeuwen; J B L Hoekstra; I J M ten Berge; J C Goslings
Journal:  Clin Vaccine Immunol       Date:  2014-09-03

Review 5.  Turf wars: exploring splenomegaly in sickle cell disease in malaria-endemic regions.

Authors:  Venée N Tubman; Julie Makani
Journal:  Br J Haematol       Date:  2017-05-11       Impact factor: 6.998

6.  Assessment of genotoxicity associated with hydroxyurea therapy in children with sickle cell anemia.

Authors:  Jonathan M Flanagan; Thad A Howard; Nicole Mortier; Svetlana L Avlasevich; Matthew P Smeltzer; Song Wu; Stephen D Dertinger; Russell E Ware
Journal:  Mutat Res       Date:  2010-03-15       Impact factor: 2.433

Review 7.  Association of chromosome damage detected as micronuclei with hematological diseases and micronutrient status.

Authors:  Ashutosh Lal; Bruce N Ames
Journal:  Mutagenesis       Date:  2011-01       Impact factor: 3.000

8.  Biomarkers of splenic function in infants with sickle cell anemia: baseline data from the BABY HUG Trial.

Authors:  Zora R Rogers; Winfred C Wang; Zhaoyu Luo; Rathi V Iyer; Eglal Shalaby-Rana; Stephen D Dertinger; Barry L Shulkin; John H Miller; Bea Files; Peter A Lane; Bruce W Thompson; Scott T Miller; Russell E Ware
Journal:  Blood       Date:  2011-01-07       Impact factor: 22.113

9.  Sensitivity to cisplatin-induced mutations and elevated chromosomal aberrations in lymphocytes from sickle cell disease patients.

Authors:  Polyanna Miranda Alves; Paulo Roberto Juliano Martins; Francisca da Luz Dias; Rommel Mario Rodríguez Burbano; Maria de Lourdes Pires Bianchi; Lusânia Maria Greggi Antunes
Journal:  Clin Exp Med       Date:  2008-04-03       Impact factor: 3.984

10.  The pediatric hydroxyurea phase III clinical trial (BABY HUG): challenges of study design.

Authors:  Bruce W Thompson; Scott T Miller; Zora R Rogers; Renee C Rees; Russell E Ware; Myron A Waclawiw; Rathi V Iyer; James F Casella; Lori Luchtman-Jones; Sohail Rana; Courtney D Thornburg; Ram V Kalpatthi; Julio C Barredo; R Clark Brown; Sharada Sarnaik; Thomas H Howard; Lori Luck; Winfred C Wang
Journal:  Pediatr Blood Cancer       Date:  2010-02       Impact factor: 3.167

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.